Perspective Therapeutics, Inc. Commitments Disclosure

The Company has been in settlement negotiations with a representative for six stockholder plaintiff firms alleging the Company violated Delaware law in its preliminary proxy statement that was disseminated to stockholders in November 2022 for the Company’s annual meeting held in December 2022. Based on these settlement negotiations to date, the Company estimates that it will settle for no more than an aggregate of $0.2 million and, therefore, recorded an estimated liability of $0.2 million during the period ended December 31, 2022, which it maintained as of December 31, 2025. This balance is included in accrued expenses in the Consolidated Balance Sheets.

In May 2025, the Company entered into a supply agreement order with the U.S. Department of Energy (DOE) under which the Company will purchase Thorium-228 from the DOE during 2025 and 2026. The supply agreement includes a “take-or-pay” provision pursuant to which the Company is committed to purchasing approximately $8.4 million of Thorium-228 during the term of the agreement.

In October 2025, the Company entered into an agreement with a general contractor to begin building modifications at its facility in the Chicago, IL metropolitan area along with preparations for the eventual installation of some of the Comecer manufacturing equipment and associated clean rooms. The Company currently estimates that the aggregate cost of these modifications will be approximately $27.5 million. However, actual costs may differ.

In the ordinary course of business, the Company may agree to provide indemnification of varying scope and terms to vendors, business partners and other parties with respect to certain matters including, but not limited to, losses arising out of breaches of such agreements or from intellectual property infringement claims made by third parties. In addition, the Company has entered into indemnification agreements with its officers and members of its Board of Directors that will require the Company to, among other things, indemnify those individuals against certain liabilities that may arise by reason of their status or service as officers or directors. The maximum amount of future payments the Company could be required to make under these indemnification agreements is, in many cases, unlimited. To date, the Company has not incurred any material costs as a result of such indemnification obligations. The Company is not currently aware of any indemnification claims and has not accrued any liabilities related to such obligations in its consolidated financial statements as of December 31, 2025 or 2024.